Cheryl R. Blanchard's most recent trade in Vigil Neuroscience Inc was a trade of 5,000 Common Stock done . Disclosure was reported to the exchange on May 22, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vigil Neuroscience Inc | Cheryl R. Blanchard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 5,000 | 5,000 | - | 0 | Common Stock | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 73,559 | 73,559 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 71,403 | 71,403 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 25,132 | 50,263 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 25,132 | 209,472 (1%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.91 per share. | 14 Mar 2025 | 12,152 | 197,320 (1%) | 0% | 15.9 | 193,338 | Common Stock |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2025 | 30,060 | 197,015 (1%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2025 | 30,060 | 0 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.79 per share. | 11 Mar 2025 | 12,675 | 184,340 (1%) | 0% | 16.8 | 212,813 | Common Stock |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 20,002 | 20,001 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 20,002 | 172,826 (1%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.62 per share. | 10 Mar 2025 | 5,871 | 166,955 (1%) | 0% | 16.6 | 97,576 | Common Stock |
| Vigil Neuroscience Inc | Cheryl R. Blanchard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 18,068 | 18,068 | - | - | Stock Option Award (Right to Buy) | |
| Vigil Neuroscience Inc | Cheryl R. Blanchard | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 May 2024 | 13,928 | 0 | - | - | Stock Option Award (Right to Buy) | |
| Vigil Neuroscience Inc | Cheryl R. Blanchard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2024 | 13,928 | 13,928 | - | - | Stock Option Award (Right to Buy) | |
| Vigil Neuroscience Inc | Cheryl R. Blanchard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2024 | 12,155 | 12,155 | - | - | Stock Option Award (Right to Buy) | |
| Vigil Neuroscience Inc | Cheryl R. Blanchard | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 May 2024 | 12,155 | 0 | - | - | Stock Option Award (Right to Buy) | |
| Vigil Neuroscience Inc | Cheryl R. Blanchard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2024 | 6,432 | 6,432 | - | - | Stock Option Award (Right to Buy) | |
| Vigil Neuroscience Inc | Cheryl R. Blanchard | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 May 2024 | 6,432 | 0 | - | - | Stock Option Award (Right to Buy) | |
| Vigil Neuroscience Inc | Cheryl R. Blanchard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2024 | 5,017 | 5,017 | - | - | Stock Option Award (Right to Buy) | |
| Vigil Neuroscience Inc | Cheryl R. Blanchard | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 May 2024 | 5,017 | 0 | - | - | Stock Option Award (Right to Buy) | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 182,699 | 182,699 | - | - | Stock Option (Right to Buy) | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 75,395 | 75,395 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 30,059 | 166,228 (1%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 30,059 | 30,060 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 20,001 | 40,003 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 20,001 | 142,642 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.79 per share. | 11 Mar 2024 | 14,534 | 151,694 (1%) | 0% | 25.8 | 374,832 | Common Stock |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 14,420 | 0 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 14,420 | 129,614 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.42 per share. | 11 Mar 2024 | 6,973 | 122,641 (0%) | 0% | 25.4 | 177,254 | Common Stock |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.42 per share. | 11 Mar 2024 | 6,473 | 136,169 (0%) | 0% | 25.4 | 164,544 | Common Stock |
| Vigil Neuroscience Inc | Cheryl R. Blanchard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 24,761 | 24,761 | - | - | Stock Option Grant (Right to Buy) | |
| Dare Bioscience Inc | Cheryl R. Blanchard | Director | 21 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | ||
| Vigil Neuroscience Inc | Cheryl R. Blanchard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 13,928 | 13,928 | - | - | Stock Option Grant (Right to Buy) | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2023 | 24,575 | 0 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2023 | 24,575 | 125,155 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.34 per share. | 26 Apr 2023 | 10,900 | 114,255 (0%) | 0% | 26.3 | 287,106 | Common Stock |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 30,060 | 113,791 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 30,060 | 60,119 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.10 per share. | 10 Mar 2023 | 13,211 | 100,580 (0%) | 0% | 26.1 | 344,807 | Common Stock |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 130,998 | 130,998 | - | - | Stock Option (Right to Buy) | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 60,004 | 60,004 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 14,419 | 14,420 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 14,419 | 87,963 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.91 per share. | 09 Mar 2023 | 4,232 | 83,731 (0%) | 0% | 26.9 | 113,883 | Common Stock |
| Vigil Neuroscience Inc | Cheryl R. Blanchard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 6,432 | 6,432 | - | - | Stock Option Grant (Right to Buy) | |
| Dare Bioscience Inc | Cheryl R. Blanchard | Director | 23 Jun 2022 | 38,000 | 38,000 | - | - | Stock Option (right to buy) | ||
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2022 | 24,576 | 72,826 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2022 | 24,576 | 24,575 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2022 | 208,821 | 208,821 | - | - | Stock Option (Right to Buy) | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2022 | 90,179 | 90,179 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Purchase of securities on an exchange or from another person at price $ 25.36 per share. | 11 Mar 2022 | 4,287 | 56,179 (0%) | 0% | 25.4 | 108,714 | Common Stock |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Purchase of securities on an exchange or from another person at price $ 25.81 per share. | 11 Mar 2022 | 3,813 | 59,992 (0%) | 0% | 25.8 | 98,429 | Common Stock |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2022 | 14,420 | 28,839 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2022 | 14,420 | 51,892 (0%) | 0% | 0 | Common Stock | |
| Dare Bioscience Inc | Cheryl R. Blanchard | Director | 24 Jun 2021 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | ||
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2021 | 2,994 | 101,644 | - | - | Stock Option (Right to Buy) | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.40 per share. | 15 Jun 2021 | 2,994 | 37,472 (0%) | 0% | 33.4 | 100,000 | Common Stock |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2021 | 24,575 | 34,478 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2021 | 24,575 | 49,151 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2021 | 108,398 | 108,398 | - | - | Stock Option (Right to Buy) | |
| Anika Therapeutics Inc. | Cheryl R. Blanchard | Director, President, CEO, Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2021 | 43,259 | 43,259 | - | - | Restricted Stock Unit |